Biologics are increasingly being marketed and used to improve outcomes for orthopaedic patients, but the requirements for evidence of safety and effectiveness vary greatly. Leaders from the AAOS Committee on Devices, Biologics & Technology discuss the regulatory landscape, the AAOS Biologics Initiative, and the Academy’s investment in this evolving area of medicine, They also explain how the new AAOS Biologics Dashboard is designed to help members navigate the approval status of biologic-based interventions. Learn more about the AAOS Biologics Initiative and access the dashboard.   Hosted by: Kristen Coultas, AAOS Advocacy Communications Director